Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/25/22
End: 06/21/24
Due: 06/21/25
Phase: N/A
Priority: Normal
Start: 10/31/16
End: 02/01/18
Due: 02/01/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder | NCT05067582 | Yamo Pharmaceuticals LLC | user2@example.com | None | 2022-01-25 | 2024-06-21 | 2025-06-21 | - | - | 2025-07-14 |
| Safety of L1-79 in Adolescent and Adult Males With Autism | NCT02947048 | Yamo Pharmaceuticals LLC | user2@example.com | None | 2016-10-31 | 2018-02-01 | 2019-02-01 | - | - | 2025-07-14 |